Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study

doi:doi:10.1038/sj.bjc.6602394

British Journal of Cancer (2005) 92, 628–630. doi:10.1038/sj.bjc.6602394 www.bjcancer.com
Published online 8 February 2005

Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study

J W Valle¹, A Dangoor¹, J Beech¹, D J Sherlock², S M Lee³, J H Scarffe⁴, R Swindell¹ and M Ranson¹

¹Christie Hospital NHS Trust, Manchester, Wilmslow Road, Manchester M20 4BX, UK
²The Pennine Acute Hospitals NHS Trust, North Manchester General Hospital, Delaunays Road, Crumpsall, Manchester M8 5RB, UK
³UCLH, The Middlesex Hospital, Mortimer Street, London W1T 3AA, UK
⁴East and North Herts NHS Trust, Lister Hospital, Coreys Mill Lane, Stevenage, Herts SG1 4AB, UK

Correspondence: Dr JW Valle, E-mail: juan.valle@christie-tr.nwest.nhs.uk

Received 29 September 2004; Revised 7 December 2004; Accepted 13 December 2004; Published online 8 February 2005.

Top

Abstract

Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m^-2, although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to progression of 2.4 months, 1-year survival of 25% and median survival of 6.5 months.